Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

Pseudomonas Clinical Trial

— Mero-Pyo  

Official title:

Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06113107
• Other study ID #: 8786
• Status: Recruiting
• Start date: March 1, 2023
• Est. completion date: March 13, 2024

Study information

• Verified date: October 2023
• Source: University Hospital, Strasbourg, France
• Contact: Yvon RUCH, MD
• Phone: 33 3 69 55 12 19
• Email: yvon.ruch[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of "standard dose" or "high dose" sensitivity. This modification seems to have favored an inappropriate overprescription of Meropenem (the only antibiotic made "at standard dose") in Pseudomonas infections sensitive to other beta-lactams. In June 2021, it was therefore decided to mask sensitivity to carbapenems by default in the rendering of Pseudomonas antibiograms when the strain was sensitive to a narrower spectrum beta-lactam ("restricted" antibiogram). The aim of this study is to evaluate the impact of these changes in the antibiogram on antibiotic prescriptions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: March 13, 2024
• Est. primary completion date: March 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major subject (=18 years old)
• Subject with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022
• Subject not opposing the reuse of their data for the purposes of this research.

Exclusion Criteria:

• Subject having expressed opposition to participating in the study,
• Pseudomonas spp strain resistant to all first-line beta-lactams (Piperacillin-Tazobactam, Ceftazidime, Céfepime and Aztreonam).
• Pseudomonas spp strain resistant to Meropenem.
• Lack of information on the antibiotic treatment undertaken.

Related Conditions & MeSH terms

• Bacteremia
• Pseudomonas
• Pseudomonas Infections

Locations

Country	Name	City	State
France	Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Meropenem prescriptions in Pseudomonas spp bacteraemia susceptible to narrow-spectrum betalactams	This study is retrospective, the analysis focuses on the medical records of patients treated at the Strasbourg University Hospital between June 1, 2018 and November 30, 2022.	Files analysed retrospectively from June 1, 2018 to November 30, 2022 will be examined